These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9292038)

  • 41. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes.
    Nalli C; Iodice A; Andreoli L; Lojacono A; Motta M; Fazzi E; Tincani A
    Lupus; 2014 May; 23(6):507-17. PubMed ID: 24763535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Lupic spinal cord diseases and antiphospholipid antibodies].
    Feki I; Ben Hmida M; Masmoudi H; Triki C; Bahloul Z; Hachicha J; Jlidi R; Mhiri C
    Rev Neurol (Paris); 1997 Mar; 153(2):138-40. PubMed ID: 9296127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies.
    Gheita TA; Abaza NM; Hammam N; Mohamed AAA; El-Gazzar II; Eissa AH
    Lupus; 2018 Jun; 27(7):1081-1087. PubMed ID: 29460701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuropsychiatric problems in systemic lupus erythematosus.
    Bennett R; Hughes GR; Bywaters EG; Holt PJ
    Br Med J; 1972 Nov; 4(5836):342-5. PubMed ID: 4344384
    [No Abstract]   [Full Text] [Related]  

  • 45. The neurologic manifestations of systemic lupus erythematosus.
    Greenberg BM
    Neurologist; 2009 May; 15(3):115-21. PubMed ID: 19430265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychiatric involvement in juvenile systemic lupus erythematosus.
    Demirkaya E; Bilginer Y; Aktay-Ayaz N; Yalnizoğlu D; Karli-Oğuz K; Işikhan V; Türker T; Topaloğlu R; Beşbaş N; Bakkaloğlu A; Ozen S
    Turk J Pediatr; 2008; 50(2):126-31. PubMed ID: 18664075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment.
    de Amorim LC; Maia FM; Rodrigues CE
    Lupus; 2017 Apr; 26(5):529-536. PubMed ID: 28394226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Psychiatric manifestations in lupus erythematosus].
    Julien CG
    Encephale; 1970; 59(4):291-312. PubMed ID: 5481585
    [No Abstract]   [Full Text] [Related]  

  • 49. Hemiballismus in systemic lupus erythematosus: possible association with antiphospholipid antibodies.
    Tam LS; Cohen MG; Li EK
    Lupus; 1995 Feb; 4(1):67-9. PubMed ID: 7767342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Neuropsychiatric manifestations in systemic lupus erythematosus].
    Alexa ID; Stoica MS; Paraschiv O; Rusu RI
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(2):322-5. PubMed ID: 17802940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre.
    Bortoluzzi A; Padovan M; Farina I; Galuppi E; De Leonardis F; Govoni M
    Reumatismo; 2012 Dec; 64(6):350-9. PubMed ID: 23285478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical manifestations of systemic lupus erythematosus, measures of disease activity, and long-term complications.
    Ginzler EM; Antoniadis I
    Curr Opin Rheumatol; 1992 Oct; 4(5):672-80. PubMed ID: 1419501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis.
    Karmochkine M; Cacoub P; Piette JC; Godeau P; Boffa MC
    Clin Exp Rheumatol; 1992; 10(6):603-5. PubMed ID: 1483313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Coronary involvement in systemic lupus erythematosus].
    Lair G; Joly P; Desrumeaux G; Thomine E; Godin M; Tron F; Letac B; Lauret P
    Ann Dermatol Venereol; 1997; 124(8):534-6. PubMed ID: 9740846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus.
    Cordeiro MF; Lloyd ME; Spalton DJ; Hughes GR
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1142-3. PubMed ID: 8089695
    [No Abstract]   [Full Text] [Related]  

  • 57. Catastrophic antiphospholipid antibody syndrome in systemic lupus erythematosus: an autopsy case report of a young woman.
    Mizuno R; Fujimoto S; Fujimoto T; Nishino T; Shiiki H; Hashimoto T; Nakamura S; Dohi K
    Intern Med; 2000 Oct; 39(10):856-9. PubMed ID: 11030215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Problems posed by the treatment of neurologic and neuropsychic manifestations of systemic lupus erythematosus].
    Corvol P; Lagrue G; Marteau R; Milliez P
    Therapeutique; 1972; 48(7):492-7. PubMed ID: 4640270
    [No Abstract]   [Full Text] [Related]  

  • 59. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?
    Laskin CA; Clark CA; Spitzer KA
    Rheum Dis Clin North Am; 2005 May; 31(2):255-72, vi. PubMed ID: 15922145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP-SLE.
    Volpe BT
    Ann N Y Acad Sci; 1997 Aug; 823():185-7. PubMed ID: 9292044
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.